Sopan Pharmaceuticals Opens IPO for General Public with High-Risk CARE NP Rating
Sopan Pharmaceuticals Limited has publicly opened its IPO from Baishakh 3, issuing 3,474,900 shares available for general investors. Applications are accepted with a limit of 10 to 11,000 shares until Baishakh 8, extendable to Baishakh 17. The company’s CARE NP Single B rating identifies it as a high-risk investment. IPOs allow new investors to buy a stake in a company, offering growth potential but with risk. This IPO adds a fresh option for Nepalese investors but calls for careful risk consideration given the rating.
- Sopan Pharmaceuticals announces a 3.47 million-share IPO, open till Baishakh 8, signaling new investor opportunities amid high risk.
Listen to Article
Natural AI Narration
Sopan Pharmaceuticals Limited has publicly opened its IPO from Baishakh 3, issuing 3,474,900 shares available for general investors. Applications are accepted with a limit of 10 to 11,000 shares until Baishakh 8, extendable to Baishakh 17. The company’s CARE NP Single B rating identifies it as a high-risk investment. IPOs allow new investors to buy a stake in a company, offering growth potential but with risk. This IPO adds a fresh option for Nepalese investors but calls for careful risk consideration given the rating.
Share this story